
    
      Study A: An open-label, prospective trial of the efficacy and safety of risperidone in the
      treatment of BPD.The study is 8 weeks in duration, with a screening visit and follow-up
      visits at the end of Weeks 1,2,3,4,6, and 8. 20 female patients, 19 years or older will be
      recruited. A full medical and psychiatric history will be taken and a physical exam will be
      performed by a sstudy physician. A psychosocial assessment will be conducted during the
      screen.

      Study B: The ofjective is to validate the UAB BRS by administering the BRS and other
      neuropsychological instruments as repeated measures over a 6 week period to 40 patients with
      BPD.
    
  